2021
A phase 1 randomized study of hemodynamic effects and pharmacokinetic interactions during concomitant use of rimegepant and sumatriptan in healthy adults
Croop R, Ivans A, Anderson M, Stringfellow J, Bertz R, Hanna M, Healy F, Stock D, Coric V, Lipton R. A phase 1 randomized study of hemodynamic effects and pharmacokinetic interactions during concomitant use of rimegepant and sumatriptan in healthy adults. Cephalalgia Reports 2021, 4: 25158163211007922. DOI: 10.1177/25158163211007922.Peer-Reviewed Original ResearchPharmacokinetic interactionsSubcutaneous sumatriptanHemodynamic effectsBlood pressureConcomitant administrationDay 1Healthy adultsInjection of sumatriptanPlacebo-controlled studyMean arterial pressureDiastolic blood pressureInjection site reactionsSystolic blood pressureTime-weighted averageAdverse eventsArterial pressureSite reactionsConcomitant useSumatriptanDay 2Day 5Dosed subjectsPlaceboSignificant differencesPhase 1
2020
Results of a Phase 1, Open-label, Single-dose, Parallel-group Study of Rimegepant 75 mg in Subjects with Hepatic Impairment (2126)
Ivans A, Stringfellow J, Coric V, Croop R. Results of a Phase 1, Open-label, Single-dose, Parallel-group Study of Rimegepant 75 mg in Subjects with Hepatic Impairment (2126). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.2126.Peer-Reviewed Original ResearchPhase 1 and 2 Safety, Tolerability and Pharmacokinetics of Single and Multiple Dose Rimegepant as Compared to the Predicted Clinically Efficacious Dose Range (2145)
Conway C, Dubowchik G, Croop R, Coric V. Phase 1 and 2 Safety, Tolerability and Pharmacokinetics of Single and Multiple Dose Rimegepant as Compared to the Predicted Clinically Efficacious Dose Range (2145). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.2145.Peer-Reviewed Original Research
2019
A Phase 1 Study to Evaluate Bioequivalence Between BHV-0223 40 mg Zydis® Sublingual Formulation and Riluzole 50 mg Oral Tablet in Healthy Volunteers (S5.005)
Qureshi I, Coric V, Gentile K, Larouche R, Tanguay M, Berman R. A Phase 1 Study to Evaluate Bioequivalence Between BHV-0223 40 mg Zydis® Sublingual Formulation and Riluzole 50 mg Oral Tablet in Healthy Volunteers (S5.005). Neurology 2019, 92 DOI: 10.1212/wnl.92.15_supplement.s5.005.Peer-Reviewed Original Research